entertainment -WSS

entertainment

author：hotspot 2025-08-25 16:34:02 - browse：3917

A handout illustration representing Google’s DeepMind subsidiary and Isomorphic Labs developed an AI model that can accurately predict how a vast universe of biomolecules interact on an atomic level. — DeepMind

Google on Wednesday unveiled an artificial intelligence tool capable of predicting the structure and interaction of a vast universe of biomolecules, a fundamental advance that may help scientists unravel poorly understood aspects of biology and disease.

The new AI, dubbed AlphaFold 3, improves upon earlier versions of the model by predicting not just the structure of proteins, but all the molecules that interact with them in cells, including RNA, DNA, ions, and other small molecules.

Most new drugs consist of small molecules designed to bind to a protein involved in disease. AlphaFold 3 opens broader avenues of exploration, allowing scientists to rapidly examine complex interactions with other molecules that may highlight new disease targets — and different ways of attacking them.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： In Spain, a hospital brews its own CAR

WSS

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Drinking less cuts risk of oral cavity, esophageal cancer: Report

Humana’s Medicare Advantage lawsuit should be tossed, DOJ says

Carvykti CAR

Lab trade group sues FDA to halt regulation of lab

Gene therapies for deafness raise the question: Do deaf people want a 'cure'?

explore

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

hotspot

Dobbs anniversary: the lost opportunity of abortion as health care

Merck to buy EyeBio, maker of eye drug, as it grows pipeline

Wildfire smoke exposes gaps in outdoor worker protections

Health insurers say they are turning to AI to cut costs, improve care

Supreme Court strikes down use of affirmative action

Focused ultrasound for uterine fibroids: an uphill battle

The cancer drug shortage isn’t new — and neither are the solutions

SEC charges former device maker CEO with $41 million fraud

Psychedelics group wrestles with new pharma identity

Carvykti CAR

focus

First Opinion Podcast: What happens when kids become caregivers?

Readout Newsletter: Moderna bird flu vaccine, Biohaven, ASCO

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

Christmas in the PICU brings some surprising joy

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

Merus drug and Keytruda shrank tumors in patients with head and neck cancer

hotspot

explore

entertainment

leisure time